$0.52 EPS Expected for Cantel Medical Corp. (CMD); Royal Bank of Canada (TSE:RY) Had 2 Bulls

November 19, 2017 - By Ellis Scott

Analysts expect Cantel Medical Corp. (NYSE:CMD) to report $0.52 EPS on December, 7 before the open.They anticipate $0.01 EPS change or 1.96% from last quarter’s $0.51 EPS. CMD’s profit would be $21.72M giving it 49.83 P/E if the $0.52 EPS is correct. After having $0.54 EPS previously, Cantel Medical Corp.’s analysts see -3.70% EPS growth. The stock decreased 0.29% or $0.3 on November 17, reaching $103.65. About 262,566 shares traded or 91.32% up from the average. Cantel Medical Corp. (NYSE:CMD) has risen 11.32% since November 19, 2016 and is uptrending. It has underperformed by 5.38% the S&P500.

Among 8 analysts covering RBC (TSE:RY), 2 have Buy rating, 1 Sell and 5 Hold. Therefore 25% are positive. RBC had 52 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Royal Bank of Canada (TSE:RY) has “Underperform” rating given on Tuesday, November 1 by Bank of America. National Bank Canada maintained Royal Bank of Canada (TSE:RY) on Tuesday, August 4 with “Sector Perform” rating. The firm earned “Market Perform” rating on Monday, February 27 by IBC. TD Securities maintained Royal Bank of Canada (TSE:RY) rating on Monday, February 27. TD Securities has “Buy” rating and $105 target. The rating was maintained by BMO Capital Markets with “Market Perform” on Thursday, August 24. The stock of Royal Bank of Canada (TSE:RY) earned “Outperform” rating by Scotia Capital on Thursday, August 27. The stock of Royal Bank of Canada (TSE:RY) earned “Sector Perform” rating by Scotia Capital on Monday, August 21. Dundee Securities maintained it with “Neutral” rating and $87 target in Wednesday, September 21 report. The firm has “Buy” rating by Desjardins Securities given on Tuesday, August 25. The stock of Royal Bank of Canada (TSE:RY) earned “Sector Perform” rating by National Bank Canada on Friday, May 26. See Royal Bank of Canada (TSE:RY) latest ratings:

01/11/2017 Broker: Canaccord Genuity Rating: Old Target: $100.00 New Target: $105.00 Target Up
25/08/2017 Broker: Barclays Capital Rating: Old Target: $94.20 New Target: $96.00 Target Up
25/08/2017 Broker: Eight Capital Rating: Old Target: $102.00 New Target: $105.00 Target Up
24/08/2017 Broker: BMO Capital Markets Rating: Market Perform New Target: $100.00 Maintain
24/08/2017 Broker: National Bank Canada Rating: Sector Perform Old Target: $99.00 New Target: $101.00 Target Down
21/08/2017 Broker: Scotia Capital Old Rating: Outperform New Rating: Sector Perform Old Target: $102.00 New Target: $100.00 Downgrade
26/05/2017 Broker: National Bank Canada Rating: Sector Perform New Target: $99.00 Maintain
26/05/2017 Broker: Scotia Capital Rating: Outperform Old Target: $101.00 New Target: $102.00 Target Up

Royal Bank of Canada , is a diversified financial services company. The company has market cap of $147.36 billion. The Firm provides personal and commercial banking, wealth management services, insurance, investor services and capital markets services and products on a global basis. It has a 13.78 P/E ratio. The Firm serves personal, business, public sector and institutional clients in Canada, the United States and approximately 40 other countries.

The stock increased 0.35% or $0.35 on November 17, reaching $100.89. About 1.22M shares traded. Royal Bank of Canada (TSE:RY) has 0.00% since November 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Cantel Medical Corp. is a provider of infection prevention services and products in the healthcare market. The company has market cap of $4.33 billion. The Company’s operating divisions include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. It has a 60.69 P/E ratio. The Company’s Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Among 2 analysts covering Cantel Medical (NYSE:CMD), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Cantel Medical had 2 analyst reports since March 17, 2017 according to SRatingsIntel. The stock has “Hold” rating by Benchmark on Friday, June 9. The firm earned “Mkt Perform” rating on Friday, March 17 by Raymond James.